Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2015
At a glance
- Drugs Rituximab (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 28 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Aug 2013 Planned End Date changed from 1 Feb 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
- 05 Nov 2012 Planned End Date changed from 1 Feb 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.